SBIR/STTR Reauthorization Act of 2025
SB 1573, the SBIR/STTR Reauthorization Act of 2025, would extend and revise the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs through 2030 and make a broad set of changes to how federal agencies administer them. The bill raises or phases in higher agency spending requirements for SBIR/STTR, extends related FAST and pilot authorities, and creates new fellowship and internship opportunities for Phase II awardees. It also expands application assistance, outreach to minority-serving institutions and underserved populations, and technical/business assistance, while directing agencies to improve websites, reporting, and data collection.
The bill also focuses heavily on commercialization and transition to market. It requires workforce training on Phase III awards, creates Technology Commercialization Officials at participating agencies, expands direct-to-Phase-II authority, and adds requirements for simplified procedures, standardized contracts, and clearer guidance for Phase III and sole-source awards. It further extends NIH and other pilot programs intended to speed award processing, improve commercialization readiness, and assess security risks.
In addition to program expansion, the bill increases oversight and transparency. It requires annual reports to Congress, a GAO report on diversification and commercialization, a longer-running award timeliness report, and a new commercialization impact assessment for mature awardees. The bill also expands database reporting to include subcontracted research institutions and their institutional classifications, including minority-serving and other designated institutions.
The bill would amend multiple provisions of Section 9 of the Small Business Act, affecting SBIR/STTR eligibility, award administration, reporting, and agency responsibilities. It also adds a new restriction on certain small business concerns majority-owned by venture capital operating companies, hedge funds, or private equity firms if they are tied to covered foreign entities, and it includes a technical change to recognize SBIC investments in the program rules.
Overall, the available context suggests the bill is framed as a reauthorization and modernization measure rather than a controversial overhaul. No committee transcripts or votes were provided, so there is no recorded floor or committee sentiment in the supplied materials. Based on the text alone, the bill appears designed to strengthen small-business innovation participation, improve commercialization outcomes, and increase oversight, while potential points of contention would likely center on higher federal spending requirements, expanded reporting burdens, foreign-ownership restrictions, and the new compliance obligations for agencies and award recipients.
SB 1573 would amend Section 9 of the Small Business Act to extend SBIR and STTR authority, update agency set-asides and pilot programs, and add new administrative, reporting, and commercialization requirements for participating federal agencies and award recipients. It would also modify related provisions governing FAST, direct-to-Phase-II awards, technical assistance, Phase III awards, and database disclosures, while adding new eligibility and safeguard rules for venture-capital-, hedge-fund-, private-equity-, and SBIC-related ownership structures. The bill would affect federal agencies that run SBIR/STTR programs, small businesses seeking awards, and research institutions that subcontract on those awards.
No committee discussion or vote history was provided, so there is no direct record of support or opposition in the supplied materials. The bill’s structure and findings-oriented provisions suggest a generally pro-innovation, pro-small-business sentiment, with emphasis on reauthorization, commercialization, and broader participation. The absence of recorded votes or transcripts means any assessment of political sentiment is limited to the bill text itself.
Likely points of contention include the bill’s increased agency spending requirements for SBIR/STTR, the expanded reporting and database obligations, and the new mandates on outreach, training, and commercialization procedures. The foreign-entity and ownership restrictions in the venture capital/private equity provisions could also draw scrutiny from affected investors and companies, while agencies may object to the operational burden of new deadlines, standardized procedures, and annual reporting. Supporters would likely emphasize broader participation, faster award processing, and stronger commercialization pathways, while critics may focus on administrative complexity and tighter eligibility rules.